Obsidian Therapeutics is developing tumor infiltrating lymphocyte (TIL) therapies for patients with intractable diseases. Conventional TIL therapies have had some success for cancer patients but are still limited by toxicity concerns caused by concomitant IL2 therapy. Using their proprietary cytoDRIVE platform, Obsidian is engineering cytoTIL therapies to express therapeutic proteins that enhance anti-tumor activity and reduce toxicity. Obsidian’s lead program, cytoTIL15, has been engineered to eliminate the need for concomitant IL2 therapy improving the magnitude and duration of response. cytoTIL15 will enter clinical trials for patients with metastatic melanoma.  

<p>Obsidian Therapeutics is developing tumor infiltrating lymphocyte (TIL) therapies for patients with intractable diseases. Conventional TIL therapies have had some success for cancer patients but are still limited by toxicity concerns caused by concomitant IL2 therapy. Using their proprietary cytoDRIVE platform, Obsidian is engineering cytoTIL therapies to express therapeutic proteins that enhance anti-tumor activity and reduce toxicity. Obsidian’s lead program, cytoTIL15, has been engineered to eliminate the need for concomitant IL2 therapy improving the magnitude and duration of response. cytoTIL15 will enter clinical trials for patients with metastatic melanoma.  </p>


Obsidian Therapeutics

General Interest Application - Obsidian Talent Community

We’re excited to develop rising talent and grateful to have worked with our Fall 2024 Co-Ops: Madison (Process Sciences), Lindsey (Process Development), Nishita (Cell Therapy), and Jessica (Cell Therapy). Shout out to our committed mentors Nirzari, Megan, Zheng, Sean, and Rachel! Wishing our Co-ops all the best in your future endeavors! 

#mentors #coops #northeasternuniversity 

Obsidian bags $115M to untether cell therapy from toxic sidekick - Fierce Biotech

Vertex taps Obsidian in controllable genetic medicines deal that could reach $75M upfront - Fierce Biotech

 Methods for identifying and using allogeneic tumor infiltrating lymphocytes to … 

Turnstone Biologics acquires Myst Therapeutics - The Science Board

MD Anderson and Obsidian Therapeutics announce collaboration to advance TIL therapies - MD Anderson Cancer Center

 The biggest private biotech investments in April 2024 

Vertex Pharma inks another R&D alliance to expand its gene-editing ambitions - MedCity News

Bristol Myers exercises option on Obsidian's CD40L cell therapy - Fierce Biotech

Obsidian Therapeutics Announces FDA Fast Track Designation for OBX-115 for the Treatment of Advanced Melanoma - Yahoo Finance

 Celsius Therapeutics Appoints Tariq Kassum President & CEO 

 Obsidian Therapeutics Announces Dr. Madan Jagasia as Chief Executive Officer and Other Leadership Appointments 

 Obsidian Therapeutics Announces FDA Fast Track Designation for OBX-115 for the Treatment of Advanced Melanoma 

 Obsidian Appoints Stehman-Breen Chief Development Officer 

Obsidian Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for OBX-115 for the Treatment of Advanced Melanoma - Business Wire

Obsidian bags $115M to untether cell therapy from toxic ...


													Obsidian Therapeutics to Present Preclinical Data Supporting OBX-115 and cytoDRiVE® Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2024
													Read More 
												


													Obsidian Therapeutics Announces Positive Clinical Data from OBX-115 in Patients with Advanced Melanoma at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
													Read More 
												

Firm Advises Novo Holdings on Obsidian’s Oversubscribed $160.5 Million Series C - Wilson Sonsini

Obsidian’s SWFT Response to COVID-19 - Genetic Engineering & Biotechnology News

The #SITC Communications Committee selected one of Obsidian’s abstracts to be presented at the SITC 2024 Annual Meeting Press Conference! Lead author Sean Smith will present the abstract to the media this afternoon.

Be sure to check out the poster, which will be available during the Annual Meeting Poster Session on November 8.

OBX-115 Earns FDA Fast Track Designation for Advanced Melanoma - OncLive

Gene Therapy Clinical Trial Pipeline Gains Momentum: 180+ - GlobeNewswire

Precision Gene Therapy on the Cusp - BioSpace

Advanced Melanoma Clinical Trial Pipeline Analysis - GlobeNewswire

Celgene strikes Obsidian deal to boost CAR-T options

Obsidian Therapeutics Joins Bedford’s Pantheon of Biotech Companies - The Bedford Citizen


													Obsidian Therapeutics Appoints Dana Alexander as Chief Technical Officer
													Read More 
												

Bristol Myers keeps Obsidian cell therapy pact rocking with multiyear extension - Fierce Biotech

 Obsidian Therapeutics Raises $160.5M in Series C Funding 

Obsidian Therapeutics Secures $160.5M Series C Financing for Innovative Cell Therapy - SynBioBeta

Obsidian Therapeutics rakes in $160M for solid tumor cell therapy program - Endpoints News

CTMC Marks One Year of Accelerating Life-Saving Cell Therapies to Patients - Business Wire

MD Anderson and Obsidian Therapeutics announce FDA clearance of IND application for novel TIL therapy OBX-115 - MD Anderson Cancer Center

Obsidian Therapeutics to Present In Vivo Anti-Tumor Efficacy Data from Novel Engineered cytoTIL15 Program at SITC 2021 - BioSpace

 Louis Lehot Leads Foley Team Representing TCG Crossover as Lead Investor in $115 Series B Financing for Obsidian Therapeutics 

On the Fast Track - Pharmaceutical Executive

Obsidian Therapeutics - Massachusetts Biotechnology Council

Celgene enters into collaboration with Obsidian Therapeutics - The Pharma Letter

 Little by Little: Real Life Lessons In Business Development 

Obsidian Therapeutics Announces Leadership Transition and Appoints Paul K. Wotton, Ph.D., as Chief Executive Officer - Business Wire

 Obsidian Therapeutics Announces Clinical & Preclinical Presentations at the American Association of Cancer ... 

Aardvark said to be planning IPO, plus other bio financings - pharmaphorum

 Obsidian Therapeutics Develops and Shares Safe Workplace Productivity Solution in Response to COVID19 

Obsidian Therapeutics Appoints Dr. Madan Jagasia as Chief Executive Officer - citybiz

Obsidian Therapeutics lands $160M Series C — but IPO still in the cards - The Business Journals

Bristol Myers inks extension to Obsidian cell therapy pact

Welcome to our most recent hires – we’re honored that you’ve chosen to join us, and excited about what we can achieve together!  
   
#obsidianrocks 


													Obsidian Therapeutics Announces Appointment of William Pao, M.D., Ph.D., to Board of Directors
													Read More 
												

Obsidian Therapeutics Raises $160.5M in Series C Funding - FinSMEs

Webinar: Fostering Diversity & Inclusion in the Workplace - BioSpace

Gilman buckles in as Arrakis raises $75M, gains momentum - Fierce Biotech


													Obsidian Therapeutics Announces FDA Fast Track Designation for OBX-115 for the Treatment of Advanced Melanoma
													Read More 
												

 Obsidian Therapeutics Appoints Heidi Hagen to Board of Directors 

Today at the #SITC TIL Symposium, our Chief Development Officer, Parameswaran Hari, will be presenting a talk titled, “Armoring Tumor-infiltrating Lymphocytes (TIL) with Membrane-bound IL15 Improves T-cell Phenotype and Enhances Persistence in Melanoma.” 
Also at the TIL Symposium, our Chief Executive Officer, Madan Jagasia, will be participating in a roundtable discussion during the SITC TIL Symposium.

Check out the full schedule and other pre-conference activities here: https://lnkd.in/g2J7kjbB


													Obsidian Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for OBX-115 for the Treatment of Advanced Melanoma
													Read More 
												

#FierceMadness: The Best Biotech Name Tournament—A champion is CROWNED - Fierce Biotech

Chip Startups Take on Nvidia... All-In on Truth Social... New IPO Value Way Below 2021...VCs Share YC Demo Day Favorites - Newcomer

 Obsidian Therapeutics eyes IPO after $115M fundraise 

 Cd40l compositions and methods for tunable regulation 

Controlling CAR-T: How scientists plan to make the engineered T cell therapy safer, and work for more cancers - Chemical & Engineering News

At Obsidian Therapeutics we believe that healthy relationships and high performing teams develop when we can be our whole selves. We make time to connect, have fun, exercise our creativity, and get to know each other's stories and interests. Below are just a few of our fall activities. 

 Compact drug responsive domains for regulation of function/abundance and … 

 Obsidian Therapeutics: Cell And Gene Therapies Company Raises $160.5 Million 

 Tumor-infiltrating lymphocytes with membrane-bound interleukin-15 and uses … 

Vertex and Obsidian Therapeutics Establish Collaboration to Discover Novel Therapies That Regulate Gene Editing - Business Wire

Fierce Biotech Fundraising Tracker '24: SiteOne snags $100M series C; Veradermics vaults with $75M - Fierce Biotech

 Compositions and systems for regulation of function/abundance and delivery of … 

Obsidian Therapeutics Announces Strategic Collaboration with Celgene to Develop Novel Cell Therapies with Tunable Immunomodulatory Factors, Opening Potential for CAR-T and Other Cellular Medicines in New Settings - Business Wire

Maria Fardis ends a two-year CEO hiatus; More leadership turnover on the menu at Galapagos - Endpoints News

 The Week’s 10 Biggest Funding Rounds: Obsidian Therapeutics And Flip Headline Another Strong Week 

 Obsidian Therapeutics Secures $160.5M Series C Financing for Innovative Cell Therapy 


													Obsidian Therapeutics Announces Additional OBX-115 Safety and Efficacy Data in Oral Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
													Read More 
												

 Obsidian Therapeutics Appoints Maria Fardis, Ph.D., to Board of Directors 

Obsidian Therapeutics Appoints Rob Ross, M.D., to Board of Directors - PR Newswire

OBX-115 Elicits Responses in Advanced or Metastatic Melanoma - OncLive

Obsidian Therapeutics is presenting two posters today at the #SITC Annual Meeting Poster Session! 

Check out abstracts 462, Antigen-responsive promoters coupled with cytoDRiVE® technology provide tight spatiotemporal regulation for tumor-infiltrating lymphocytes (TIL) expressing membrane-bound IL12, and 457, Engineered tumor-infiltrating lymphocytes (TIL) with co-regulated membrane-bound IL15 (mbIL15) and LIGHT (TNFSF14) generate significant antitumor efficacy in fibrotic tumor models.

enGene Appoints Ryan Daws as Chief Financial Officer - PR Newswire

 Obsidian raises $160.5 million in oversubscribed Series C financing 

Today Obsidian announced the publication of 3 abstracts for poster presentations at #SITC2024. Obsidian will share preclinical data supporting the potential of its cytoDRiVE platform to enable a more patient-centric, core needle biopsy tumor tissue procurement procedure for OBX-115 manufacturing in non-small cell lung cancer (NSCLC) and to potentially expand the therapeutic window and application of potent, immune-modulating cytokines for armored cell therapies.  

See more here: https://lnkd.in/efM9i6Py 

Obsidian Raises $160M+ to Advance Novel Solid Tumor Immunotherapy - Inside Precision Medicine

Wotton replaces Gilman as CEO of cell, gene therapy startup Obsidian - Fierce Biotech

Obsidian Therapeutics to Present Preclinical Data Supporting OBX-115 and cytoDRiVE® Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2024 - Business Wire

 被BMS收购后，Celgene先后与两家企业建立了免疫肿瘤合作关系 

 Obsidian Therapeutics’ Post 

Obsidian Therapeutics Announces Extension of Multi-Year Collaboration Agreement with Bristol Myers Squibb - PR Newswire

Obsidian Therapeutics Announces Closing of $115 Million Series B Financing - PR Newswire

Obsidian Therapeutics is presenting today at the #SITC Annual Meeting Poster Session! 

Check out abstract 444: Potential feasibility of core needle biopsy tumor tissue procurement method for TIL cell therapy with OBX-115 in non-small cell lung cancer (NSCLC).

Tunable CAR-T Therapies: A New Generation of Small, Molecule-Controlled Therapies - BioSpace

Obsidian Therapeutics to Present Significant Advancements to its Proprietary cytoDRiVE® Technology at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting 2022 - PR Newswire

Today at #SITC, Obsidian is presenting two preclinical posters at the SITC Immune Engineering Workshop, which will be held from 3:10-5:00pm CT.

Learn more here: https://lnkd.in/eEBaPCJP

 Biopharma Company Obsidian Therapeutics Raises $160.5M 

Bristol Myers exercises option on Obsidian's CD40L cell ...

Our CEO, Madan Jagasia, is participating in two events at the TIL Therapies Summit in Boston today: At 8:30am, Madan is featured in the Industry Leaders Fireside Chat, titled, “Challenges & Opportunities in Expanding Beyond Melanoma”, along with panelists from KSQ Therapeutics, GRIT Biotechnology & Iovance Biotherapeutics. 
 
Madan is also presenting on our TIL cell therapy, OBX-115, at 3:30 pm: “Improving Efficacy and Minimizing Safety Risks of TIL Cell Therapy by Rational Engineering of TIL”
 
See more here: https://til-therapies.com/


													Obsidian Therapeutics to Present Clinical Data from OBX-115, its Engineered TIL Cell Therapy, for Patients with Advanced Solid Tumors in Oral Presentation at the 2024 ASCO Annual Meeting
													Read More 
												

Top 20 biotech startups raise $2.9B in Q1 2024 funding surge - Drug Discovery & Development

 Obsidian Therapeutics Appoints Jeffrey Trigilio as Chief Financial Officer 

 The Week's 10 Biggest Funding Rounds: Obsidian Therapeutics And Flip Headline Another Strong Week 

Obsidian Therapeutics Announces Positive Interim Top-Line Clinical Data for OBX-115 Engineered TIL Cell Therapy in Advanced or Metastatic Melanoma Post-Anti-PD1 Therapy - Business Wire

The Week’s 10 Biggest Funding Rounds: Obsidian Therapeutics And Flip Headline Another Strong Week - Crunchbase News

Obsidian Therapeutics

Business:

Drug notes:

About: